Fundamental Analysis of ANIXA BIOSCIENCES INC(NASDAQ:ANIX) stock

Fundamental Rating

ANIX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ANIX as it has an excellent financial health rating, but there are worries on the profitability. ANIX is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

ANIX had negative earnings in the past year.

In the past year ANIX has reported a negative cash flow from operations.

In the past 5 years ANIX always reported negative net income.

ANIX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ANIX has a Return On Assets (-42.35%) which is comparable to the rest of the industry.

ANIX's Return On Equity of -43.67% is fine compared to the rest of the industry. ANIX outperforms 71.79% of its industry peers.

		Industry Rank	Sector Rank
ROA	-42.35%
ROE	-43.67%
ROIC	N/A

ROA(3y)-39.63%

ROA(5y)-82.02%

ROE(3y)-41.22%

ROE(5y)-92.08%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ANIX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, ANIX has more shares outstanding

ANIX has more shares outstanding than it did 5 years ago.

ANIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

ANIX has an Altman-Z score of 64.16. This indicates that ANIX is financially healthy and has little risk of bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 64.16, ANIX belongs to the top of the industry, outperforming 98.29% of the companies in the same industry.

ANIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	64.16

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 15.19 indicates that ANIX has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 15.19, ANIX belongs to the top of the industry, outperforming 90.60% of the companies in the same industry.

A Quick Ratio of 15.19 indicates that ANIX has no problem at all paying its short term obligations.

The Quick ratio of ANIX (15.19) is better than 90.60% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	15.19
Quick Ratio	15.19

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ANIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.07%, which is quite good.

Measured over the past years, ANIX shows a very negative growth in Revenue. The Revenue has been decreasing by -28.32% on average per year.

EPS 1Y (TTM)17.07%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-25%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y-28.32%

Revenue growth Q2QN/A

3.2 Future

ANIX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.62% yearly.

The Revenue is expected to grow by 179.16% on average over the next years. This is a very strong growth

EPS Next Y-40.25%

EPS Next 2Y-19.77%

EPS Next 3Y12.56%

EPS Next 5Y41.62%

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5Y179.16%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ANIX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ANIX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ANIX's earnings are expected to grow with 12.56% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-19.77%

EPS Next 3Y12.56%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ANIX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ANIXA BIOSCIENCES INC

NASDAQ:ANIX (4/19/2024, 10:22:53 AM)

3.1

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap98.89M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-42.35%
ROE	-43.67%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	15.19
Quick Ratio	15.19
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)17.07%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-40.25%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ANIXA BIOSCIENCES INC (ANIX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens